FDA panel to discuss Celltrion biosimilar

FDA's Oncologic Drugs Advisory Committee will meet on Oct. 10 to review a resubmitted BLA for CT-P10 from Celltrion Inc. (KOSDAQ:068270), the company's biosimilar of Rituxan/MabThera rituximab.